BIOMAT Database Logo BIOMAT Database Logo

[Polychemotherapy of Hodgkin's disease. Long-term results in 226 cases]. 1977

C Jacquillat, and G Auclerc, and M F Gemon-Auclerc, and M Weil, and C Chastang, and M Boiron, and J Bernard

UI MeSH Term Description Entries
D008466 Mechlorethamine A biologic alkylating agent that exerts its cytotoxic effects by forming DNA ADDUCTS and DNA interstrand crosslinks, thereby inhibiting rapidly proliferating cells. The hydrochloride is an antineoplastic agent used to treat HODGKIN DISEASE and LYMPHOMA. Chlorethazine,Chlormethine,Mechlorethamine Oxide,Mustine,Nitrogen Mustard,Nitrogen Mustard N-Oxide,Bis(2-chloroethyl)methylamine,Caryolysine,Cloramin,Embichin,Mechlorethamine Hydrochloride,Mechlorethamine Hydrochloride N-Oxide,Mechlorethamine N-Oxide,Methylchlorethamine,Mitomen,Mustargen,NSC-10107,NSC-762,Nitrogranulogen,Nitromin,Hydrochloride N-Oxide, Mechlorethamine,Hydrochloride, Mechlorethamine,Mechlorethamine Hydrochloride N Oxide,Mechlorethamine N Oxide,N-Oxide, Mechlorethamine Hydrochloride,N-Oxide, Nitrogen Mustard,NSC 10107,NSC 762,NSC10107,NSC762,Nitrogen Mustard N Oxide
D011241 Prednisone A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver. Dehydrocortisone,delta-Cortisone,Apo-Prednisone,Cortan,Cortancyl,Cutason,Dacortin,Decortin,Decortisyl,Deltasone,Encorton,Encortone,Enkortolon,Kortancyl,Liquid Pred,Meticorten,Orasone,Panafcort,Panasol,Predni Tablinen,Prednidib,Predniment,Prednison Acsis,Prednison Galen,Prednison Hexal,Pronisone,Rectodelt,Sone,Sterapred,Ultracorten,Winpred,Acsis, Prednison
D011344 Procarbazine An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. Matulane,Natulan,Procarbazine Hydrochloride,Procarbazine Monohydrobromide,Procarbazine Monohydrochloride,Hydrochloride, Procarbazine,Monohydrobromide, Procarbazine,Monohydrochloride, Procarbazine
D012075 Remission, Spontaneous A spontaneous diminution or abatement of a disease over time, without formal treatment. Spontaneous Healing,Spontaneous Regression,Spontaneous Remission,Healing, Spontaneous,Regression, Spontaneous,Spontaneous Healings,Spontaneous Regressions
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006689 Hodgkin Disease A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen. Granuloma, Hodgkin,Granuloma, Malignant,Hodgkin Lymphoma,Lymphogranuloma, Malignant,Granuloma, Hodgkin's,Granuloma, Hodgkins,Hodgkin Lymphoma, Adult,Hodgkin's Disease,Hodgkin's Lymphoma,Hodgkins Disease,Lymphocyte Depletion Hodgkin's Lymphoma,Lymphocyte-Rich Classical Hodgkin's Lymphoma,Mixed Cellularity Hodgkin's Lymphoma,Nodular Lymphocyte-Predominant Hodgkin's Lymphoma,Nodular Sclerosing Hodgkin's Lymphoma,Adult Hodgkin Lymphoma,Disease, Hodgkin,Disease, Hodgkin's,Disease, Hodgkins,Hodgkin Granuloma,Hodgkin's Granuloma,Hodgkins Granuloma,Hodgkins Lymphoma,Lymphocyte Rich Classical Hodgkin's Lymphoma,Lymphogranulomas, Malignant,Lymphoma, Hodgkin,Lymphoma, Hodgkin's,Malignant Granuloma,Malignant Granulomas,Malignant Lymphogranuloma,Malignant Lymphogranulomas,Nodular Lymphocyte Predominant Hodgkin's Lymphoma
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D014750 Vincristine An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.) Leurocristine,Citomid,Farmistin,Oncovin,Oncovine,Onkocristin,Vincasar,Vincasar PFS,Vincristin Bristol,Vincristin medac,Vincristine Sulfate,Vincrisul,Vintec,cellcristin,PFS, Vincasar,Sulfate, Vincristine

Related Publications

C Jacquillat, and G Auclerc, and M F Gemon-Auclerc, and M Weil, and C Chastang, and M Boiron, and J Bernard
[Long-term results of polychemotherapy for Hodgkin's disease in children].
January 2003, Voprosy onkologii,
C Jacquillat, and G Auclerc, and M F Gemon-Auclerc, and M Weil, and C Chastang, and M Boiron, and J Bernard
[Long-term follow-up study of postoperative revascularization in childhood moyamoya disease: results of 226 cases].
June 1998, Zhonghua wai ke za zhi [Chinese journal of surgery],
C Jacquillat, and G Auclerc, and M F Gemon-Auclerc, and M Weil, and C Chastang, and M Boiron, and J Bernard
[Hodgkin's disease in childhood: long term results].
April 1982, Archives francaises de pediatrie,
C Jacquillat, and G Auclerc, and M F Gemon-Auclerc, and M Weil, and C Chastang, and M Boiron, and J Bernard
[Long-term results of 100 cases of Hodgkin's disease treated with chemotherapy].
January 1967, Tumori,
C Jacquillat, and G Auclerc, and M F Gemon-Auclerc, and M Weil, and C Chastang, and M Boiron, and J Bernard
[Hodgkin's disease. Analysis of long term results].
January 1966, Nouvelle revue francaise d'hematologie,
C Jacquillat, and G Auclerc, and M F Gemon-Auclerc, and M Weil, and C Chastang, and M Boiron, and J Bernard
[Polychemotherapy of Hodgkin's disease].
June 1970, L'union medicale du Canada,
C Jacquillat, and G Auclerc, and M F Gemon-Auclerc, and M Weil, and C Chastang, and M Boiron, and J Bernard
Long-term results of radical radiotherapy in Hodgkin's disease.
June 1966, Cancer research,
C Jacquillat, and G Auclerc, and M F Gemon-Auclerc, and M Weil, and C Chastang, and M Boiron, and J Bernard
[Cyclic polychemotherapy of Hodgkin's disease].
October 1984, Orvosi hetilap,
C Jacquillat, and G Auclerc, and M F Gemon-Auclerc, and M Weil, and C Chastang, and M Boiron, and J Bernard
[Long-term results obtained by radiotherapy in Hodgkin's disease].
January 1966, Nouvelle revue francaise d'hematologie,
C Jacquillat, and G Auclerc, and M F Gemon-Auclerc, and M Weil, and C Chastang, and M Boiron, and J Bernard
[Long-term results of the treatment of Hodgkin's disease].
January 1966, Nouvelle revue francaise d'hematologie,
Copied contents to your clipboard!